Hct noted to be 10 and patient was transfused 7 units of PRBC to an Hct of 30.
She reports increased menstrual bleeding x 6 months with worsening on LMP of [**2180-4-28**].
Evaluation at OSH also revealed bilateral DVTs.
TVUS (OSH): 7.6x3.3x4.5cm Rt adnexal mass & Rt cyst 6.7x5.7x5.4cm w/o septations.
MRI (OSH): 2-3cm [**MD Number(3) 63509**] x2, large cervical mass with parametrial invasion and irreg on L side, mass comes up to sigmoid with possible invasion, R ureter compressed between adnexal mass and enlarged thick-walled uterus.
CT Torso: small effusions, +PA and pelvic nodes, gallstones, fatty liver 4.
-CA-125: 40, AFP <1, CEA1.8 -EUA: 3-4 cm friable/fungating mass on cervix with right parametrial and anterior vaginal wall extention - PET/CT: abnl uptake in retroperitoneal [**MD Number(3) 63511**] colonic polyp; L flank swelling w/ fat stranding; lower abd collection separate from bowel - colonoscopy ([**First Name4 (NamePattern1) **] [**Last Name (NamePattern1) **]): poss met invasion - bx non diagnostic, necrotic tissue - nl [**Last Name (un) 3907**] [**5-10**] -Rad Onc consult: for palliative chemoradiation with Dr. [**Last Name (STitle) 46811**] at [**Hospital1 1474**] -Heme Onc consult: needs heme/onc at [**Hospital1 1474**] - contact[**Name (NI) **] Dr. [**Last Name (STitle) 63512**] [**Telephone/Fax (1) 63513**]  2.
Blood Loss Anemia: hct [**5-16**]: 28.7; transfuse for goal > 30 for chemoradiation     -s/p 7 units PRBCs on [**4-30**]     -s/p 1u PRBC on [**5-7**]     -s/p 2u PRBC on [**5-9**]     -s/p 2u [**5-14**]     -active T+C      b. B/L DVT: R marked improvement; L mild improvement     -s/p IVC filter plcmt ([**4-30**])     -was maintained on heparin drip, switched to [**Hospital1 **] lovenox [**5-12**] pm  5.
ID: R flank/chest pain [**5-13**] - CXR atelectasis vs consolidation; clinically favor atelectasis.
Resp: CXR [**5-13**] atelectasis vs consolidation, clinically favor atelectasis; maintaining O2 sat 95% on RA  10.
Enoxaparin Sodium 80 mg/0.8 mL Syringe Sig: One (1) Subcutaneous Q12H (every 12 hours).
Dolasetron Mesylate 12.5 mg/0.625 mL Solution Sig: One (1) Intravenous  Q8H (every 8 hours) as needed.
